Tremelimumab in combination with tumor ablation represents a potentially novel treatment modality for patients with advanced HCC, that leads to the accumulation of intratumoral CD8+ T cells in conjunction with reduction in HCV viral load [127]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.